MOBERG DERMA BECOMES MOBERG PHARMA

Moberg Derma AB (OMX: MOB) announced today that the Swedish Companies
Registration Office has granted the company's application for a name change to
Moberg Pharma AB (publ), in accordance with the decision of the AGM on 23 April
2013.
The rationale for the name change is that the business, through the acquisition
of Alterna LLC (renamed Moberg Pharma North America LLC), encompasses more than
only skin conditions. However, skin conditions and topical drug delivery will
remain core areas of the company.

"The name change is a natural step in the company's development. Today, our
activities cover other areas than skin conditions and as we continue to build a
different kind of pharmaceutical company, we expect to operate in additional
therapeutic areas," said Peter Wolpert, CEO of Moberg Pharma.

Updated contact details and website address are provided below. The company's
shares will continue to trade under the ticker symbol MOB on the NASDAQ OMX
Nordic Exchange Stockholm.

About this information
Moberg Pharma discloses the information provided herein pursuant to the
Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 12:00 noon (CET) on May 2nd, 2013.
For further information, please contact:
Peter Wolpert, President and CEO
Mobil: +46 (0)70-735 71 35
Email: peter.wolpert@mobergpharma.se (peter.wolpert@mobergderma.se)

Magnus Persson, IR
Mobil: +46 (0)73-355 26 01
Email: magnus.persson@mobergpharma.se (magnus.persson@mobergderma.se)
About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
direct sales through its own sales organization in the US and sales through
distributors in more than 35 countries. The company’s product portfolio includes
topical products for the treatment of skin disorders and pain under the brands
Kerasal®, Jointflex®, Emtrix® and Kaprolac®. Emtrix® (NaloxTM in many markets)
is the leading product for the treatment of nail disorders in the Nordic market.
The portfolio is developed further through acquisitions and in-licensing of
products as well as product development with focus on innovative drug delivery
based on proven compounds. Moberg Pharma has offices in Stockholm and New Jersey
and the company’s share (OMX: MOB) is listed on the Small Cap list of the NASDAQ
OMX Nordic Exchange Stockholm. For further information, please visit:
www.mobergpharma.se.